Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups.
Hurler L, Szilágyi Á, Mescia F, Bergamaschi L, Mező B, Sinkovits G, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Würzner R; Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration; Lyons PA, Toonen EJM, Prohászka Z.
Hurler L, et al.
Front Immunol. 2023 Mar 27;14:1162171. doi: 10.3389/fimmu.2023.1162171. eCollection 2023.
Front Immunol. 2023.
PMID: 37051252
Free PMC article.